S&P 500   3,768.47
DOW   30,924.14
QQQ   304.10
S&P 500   3,768.47
DOW   30,924.14
QQQ   304.10
S&P 500   3,768.47
DOW   30,924.14
QQQ   304.10
S&P 500   3,768.47
DOW   30,924.14
QQQ   304.10
Log in

Syndax Pharmaceuticals Price Target, Predictions & Analyst Ratings

+0.39 (+1.76 %)
(As of 03/4/2021 12:00 AM ET)
Today's Range
Now: $22.58
50-Day Range
MA: $22.00
52-Week Range
Now: $22.58
Volume1.58 million shs
Average Volume586,544 shs
Market Capitalization$922.82 million
P/E RatioN/A
Dividend YieldN/A

Analyst Ratings

Syndax Pharmaceuticals (NASDAQ:SNDX) Price Target and Consensus Rating

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
12 Wall Street analysts have issued ratings and price targets for Syndax Pharmaceuticals in the last 12 months. Their average twelve-month price target is $27.50, predicting that the stock has a possible upside of 21.79%. The high price target for SNDX is $33.00 and the low price target for SNDX is $15.00. There are currently 2 hold ratings and 10 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
SNDX Consensus Rating: BuyBuyBuyBuy
SNDX Consensus Rating Score: 2.832.822.752.78
SNDX Analyst Ratings: 0 Sell Rating(s)
2 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
SNDX Consensus Price Target: $27.50$27.27$24.50$21.38
SNDX Price Target Upside: 21.79% upside38.31% upside42.76% upside47.82% upside

Syndax Pharmaceuticals (NASDAQ:SNDX) Consensus Price Target History

Average Share Price and Price Target by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Syndax Pharmaceuticals (NASDAQ:SNDX) Analyst Ratings History

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/18/2021B. RileyInitiated CoverageBuy$30.00High
12/8/2020Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon RussellBoost Price TargetBuy$23.00 ➝ $31.00High
12/8/2020Smith Barney CitigroupBoost Price TargetBuy$23.00 ➝ $31.00Low
12/7/2020Morgan StanleyBoost Price TargetEqual Weight$17.00 ➝ $25.00Medium
12/7/2020BTIG ResearchBoost Price TargetBuy$26.00 ➝ $32.00Medium
12/7/2020BarclaysBoost Price TargetOverweight$29.00 ➝ $31.00High
12/2/2020Stifel NicolausInitiated CoverageBuy$32.00High
5/25/2020NomuraReiterated RatingBuy$31.00Low
5/22/2020HC WainwrightDowngradeBuy ➝ Neutral$25.00 ➝ $15.00High
4/28/2020Robert W. BairdBoost Price TargetOutperform$27.00 ➝ $33.00High
3/26/2020Nomura SecuritiesReiterated RatingBuy$16.00Medium
11/8/2019CowenReiterated RatingBuyLow
(Data available from 3/5/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
This page was last updated on 3/5/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.